ARV-825

3 papers2 findings

PubChem 92044400 ChEBI 230507

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 1 country

Funders: Japan Agency for Medical Research and Development and 5 more

Animals1
Model organisms1

Outcomes

Viability

downin D. dorotocephala1

1 study

ARV-825 decreases viability in D. dorotocephala (91.7% survival with 1μM ARV-825 reduced to 25% survival in 10 μM ARV-825).
“This demonstrated a concentration-dependent reduction in viability, 91.7% survival with 1μM ARV-825 reduced to 25% survival in 10 μM ARV-825.”
Model organisms
Viability of Dugesia dorotocephala Planaria with the Senolytic Drug ARV-825
microPublication biology6 Feb 2026

Selective elimination of senescent cells

upin mouse cells1

1 study

ARV-825 induces selective elimination of senescent cells in mouse cells.
“identifying the Bcl-2 inhibitor ABT263 and the BET inhibitor ARV825 as most effective senolytics across fibroblast and epithelial senescence models.”
Cellscomparison of 21 senolytic agents across senescence modelsfibroblast and epithelial cells
Comparative analysis of senolytic drugs reveals mitochondrial determinants of efficacy and resistance
Nature aging29 Jan 2026